The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who ...

Using vedolizumab first, before tumor necrosis facor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

Hospitalized patients with opioid use disorder (OUD) who received in-hospital addiction consultation services were more ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The Nashville-based managed services organization now serves 1300 providers and 747,000 patients across 420 sites of care.

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

Taxing imports to the US could spell major consequences for health care prices, innovation, and access, as a great amount of ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Patient navigation and mailed outreach improved colorectal cancer screening rates in rural clinics, but follow-up colonoscopy ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...